Biosimilars Policy Roundup for October 2022—Podcast Edition

On this episode of Not So Different, we recap some of the biosimilar policy news from the around the world during October, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

On this episode of Not So Different, we recap some of the biosimilar policy news from the around the world during October, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.

Show notes

Saskatchewan Becomes Sixth Canadian Province to Implement a Biosimilar Switching Policy

Advocacy Organization Calls for Ontario to Switch Patients to Biosimilars

BioRationality: a Dr Sarfaraz Niazi Column—The EMA Declares Biosimilars Interchangeable

Biden Authorizes Update to the Biosimilar User Fee Act Through 2027

New Bill Aims to Remove Barriers to Interchangeable Biosimilars

Amgen Report: Biosimilars Have Saved $21 Billion in 6 Years

It’ll Take a Village: Collaborative Efforts Needed to Increase Ophthalmology Biosimilar Uptake

Order of Operations: Managing Biosimilars While Maintaining Operational Efficiency

Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy